Zykadia

Chemical Nameceritinib
Dosage FormTablet (oral; 150 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyNovartis
Approval Year2014

Indication

  • For the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Last updated on 7/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zykadia (ceritinib) Prescribing Information.2021Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non‑small cell lung cancer: a systematic review and meta‑analysis.2022Investigational New Drugs
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer. 2022Cochrane Database of Systematic Reviews
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. 2021BMC Cancer
Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: a systematic review and meta-analysis2020Journal of Clinical Pharmacy and Therapeutics
The incidence of ALK inhibitor-related pneumonitis in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.2019Lung Cancer
Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review.2019Critical Reviews in Oncology/Hematology
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer.2019Medicine
Ceritinib alone for crizotinib-naive versus crizotinib-pretreated for management of anaplastic lymphoma kinase-rearrangement non-small-cell lung cancer: a systematic review.2018Clinical Lung Cancer
ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis.2018PLoS One
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer.2018Future Oncology
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.2018Oncotarget
Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.2018Oncotarget